AMD

Types of tests and criteria that can be used to diagnose conditions such as age-related macular degeneration, diabetic macular edema, and inherited retinal disease.

A panel of global experts who treat patients with retinal diseases suggest causes of age-related macular degeneration, diabetic macular edema, and inherited retinal disease.

In a study, a single intravitreal injection of ADVM-022 had a 99% reduction in the mean annualized frequency of anti-VEGF injections.

Investigators corroborate the hypothesis that retinal ganglion cells with dendrites stratified in the off sublaminae could be damaged.

According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.

Amid pandemic, physicians and patients have embraced remote technology.

An updated PDS procedure reduces complications.

The not-for-profit vision and healthcare organization breaks ground on premier Technology Center for assistive technology for people with vision loss.

The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.

RGX-314 eyed by investigators as a therapeutic option for exudative AMD.

Preexisting neutralizing antibodies associated with the inflammatory changes.

Experts discuss durability of action and atrophy inhibitor among primary treatment goals.

Uwe Oberheide, MD, discusses the key findings of his virtual ARVO 2021 presentation on modeling of IOLs for patients with AMD by ray-tracing.

Safety data on non-clinician-led services have shown a low complication rate

Investigators set out to determine if treatment crosses blood-retina barrier

Worldwide increase in technologies for ophthalmic use is dramatic

Expert panelists provide an overview of current unmet needs in wet AMD care and discuss the potential for improving clinical outcomes and treatment burden.

Key opinion leaders in ophthalmology comment on the potential role of alternative targets beyond VEGF-A including VEGF-C/VEGF-D and tyrosine kinase inhibitors.

A panel of expert ophthalmologists provides insight into emerging clinical trial data on new molecules, surgical implants, and gene therapy in wet AMD.

A panel of experts discusses nonexudative neovascular AMD and challenges associated with diagnostic imaging such as OCT-A and fluorescein angiography.

Key opinion leaders discuss factors to consider when selecting treatments in wet AMD including insurance considerations and degree of clinical response.

Panelists consider the theoretical systemic safety of anti-VEGF agents in wet AMD and discuss their role in the management of patients with risk factors.

Experts compare the safety and efficacy of agents currently available for wet AMD treatment and emphasize the importance of post-marketing surveillance.

Panelists give insight into the role of anti-VEGF therapy for wet AMD treatment and share personal experiences counseling patients on the goals of therapy.

Experts share best practices for managing the treatment burden of wet AMD including treat-and-extend, loading doses, monitoring, and hybrid telemedicine.